Focused On-demand Library for Tyrosine-protein kinase Yes

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We employ our advanced, specialised process to create targeted libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P07947

UPID:

YES_HUMAN

Alternative names:

Proto-oncogene c-Yes; p61-Yes

Alternative UPACC:

P07947; A6NLB3; D3DUH1

Background:

Tyrosine-protein kinase Yes, also known as Proto-oncogene c-Yes and p61-Yes, plays a pivotal role in cell growth, survival, apoptosis, and differentiation. It is activated by receptor tyrosine kinases such as EGFR and PDGFR, leading to phosphorylation of downstream substrates. This kinase is essential for epithelial tight junction assembly, cell-cell adhesion, and T-cell migration, highlighting its importance in cellular communication and immune response.

Therapeutic significance:

Understanding the role of Tyrosine-protein kinase Yes could open doors to potential therapeutic strategies. Its involvement in critical cellular processes such as cell cycle progression and cytokinesis underscores its potential as a target in cancer therapy and immune modulation.